Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer (2011)

  • Authors:
  • USP affiliated authors: CARRARA, HELIO HUMBERTO ANGOTTI - FMRP ; TIÉZZI, DANIEL GUIMARÃES - FMRP
  • USP Schools: FMRP; FMRP
  • DOI: 10.1007/s12032-010-9711-0
  • Subjects: NEOPLASIAS MAMÁRIAS (CIRURGIA;CONSERVAÇÃO); QUIMIOTERAPIA ADJUVANTE
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    DOI or search this record in
    Informações sobre o DOI: 10.1007/s12032-010-9711-0 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Informações sobre o Citescore
  • Título: Medical Oncology

    ISSN: 1357-0560

    Citescore - 2017: 2.04

    SJR - 2017: 0.757

    SNIP - 2017: 0.591


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FMRP2170830pcd 2170830 estantes deslizantes
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      ANDRADE, J. M.; CARRARA, Helio Humberto Angotti; PIMENTEL, Flanklin Fernandes; et al. Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer. Medical Oncology, Totowa, v. 28, p. s65-s69, 2011. DOI: 10.1007/s12032-010-9711-0.
    • APA

      Andrade, J. M., Carrara, H. H. A., Pimentel, F. F., Marana, H. R. C., Macchetti, A. H., Mouro, L. R., et al. (2011). Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer. Medical Oncology, 28, s65-s69. doi:10.1007/s12032-010-9711-0
    • NLM

      Andrade JM, Carrara HHA, Pimentel FF, Marana HRC, Macchetti AH, Mouro LR, Zola FE, Tiezzi DG. Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer. Medical Oncology. 2011 ; 28 s65-s69.
    • Vancouver

      Andrade JM, Carrara HHA, Pimentel FF, Marana HRC, Macchetti AH, Mouro LR, Zola FE, Tiezzi DG. Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer. Medical Oncology. 2011 ; 28 s65-s69.

    Referências citadas na obra
    Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019–27.
    Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, et al. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol. 2007;25(15):2012–8.
    Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778–85.
    Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483–93.
    Agarwal G, Ramakant P, Forgach ER, Rendon JC, Chaparro JM, Basurto CS, et al. Breast cancer care in developing countries. World J Surg. 2009;33(10):2069–76.
    Jakesz R. Breast cancer in developing countries: challenges for multidisciplinary care. Breast Care (Basel). 2008;3(1):4–5.
    Whitman GJ, Strom EA. Workup and staging of locally advanced breast cancer. Semin Radiat Oncol. 2009;19(4):211–21.
    Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez HL, Martin M, et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. Sep 9.
    Darb-Esfahani S, Loibl S, Muller BM, Roller M, Denkert C, Komor M, et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res. 2009;11(5):R69.
    Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. Sep;17(9):2411-8.
    Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. Apr 20;28(12):2024-31.
    Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004;22(12):2303–12.
    Beriwal S, Schwartz GF, Komarnicky L, Garcia-Young JA. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Breast J. 2006;12(2):159–64.
    Tiezzi DG, Andrade JM, Marana HR, Zola FE, Peria FM. Breast conserving surgery after neoadjuvant therapy for large primary breast cancer. Eur J Surg Oncol. 2008;34(8):863–7.
    Fitzal F, Riedl O, Mittlbock M, Dubsky P, Bartsch R, Steger G, et al. Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study. Breast cancer research and treatment. Sep 17.
    Cox CE, Cox JM, White LB, Stowell NG, Clark JD, Allred N, et al. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. Ann Surg Oncol. 2006;13(4):483–90.
    Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999;230(1):72–8.
    Schrenk P, Hochreiner G, Fridrik M, Wayand W. Sentinel node biopsy performed before preoperative chemotherapy for axillary lymph node staging in breast cancer. Breast J. 2003;9(4):282–7.
    van Rijk MC, Nieweg OE, Rutgers EJ, Oldenburg HS, Olmos RV, Hoefnagel CA, et al. Sentinel node biopsy before neoadjuvant chemotherapy spares breast cancer patients axillary lymph node dissection. Ann Surg Oncol. 2006;13(4):475–9.
    Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23(36):9304–11.